UPDATE: Aegis Capital Raises PT on Catalyst Pharmaceutical Following 2Q 2013 Financial Results

In a report published Friday, Aegis Capital analyst Raghuram Selvaraju reiterated a Buy rating on Catalyst Pharmaceutical (NASDAQ: CPRX ), and raised the price target from $2.50 to $3.00. In the report, Aegis Capital noted, “Earlier this week, Catalyst reported financial results for 2Q 2013. While the net loss per share